EXECUTIVE DEFERRED COMPENSATION PLAN RECOMMENDATION
COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS
The Pharmacopeia Deferred Compensation Plan is designed to allow key executives and members of the Board
of Directors to defer compensation from federal taxes and to provide a vehicle for tax-deferred investment
growth. It also functions as a retention mechanism through the use of a vesting schedule for Company-made
matches and bonus awards. The planned effective date of the plan is 1/1/00.
Participation in this plan is restricted to full, US-based Vice Presidents of the Company and members of its
Board of Directors, and includes the below named eligible participants who represent approximately 3.5% of the
total US-based employee population. New participants must be approved by the Board of Directors.
SCHEDULE OF CURRENT PARTICIPANTS:
Joe Mollica-CEO, Saiid Zarrabian-COO, Bruce Myers-CFO, Jack Baldwin-CSO, Tom Carney-General
Counsel, Steve Herbert-MSI VP Life Sciences Software Sales, Akira Niwayama-VP Asia Pacific Operations,
John Newsam-MSI CSO, Steve Spearman-EVP Drug Discovery Services, Dick Walsh-SVP Business Dev &
Mktg, Scott Kahn-VP Life Sciences Software R&D, John Babiak-VP, Technology, Frank Baldino-BOD
Member, Paul Bartlett-BOD Member, Peter Booth-BOD Member, Gary Costley-BOD Member, Edith Martin-
BOD Member, Charles Sanders-BOD Member
ANNUAL DEFERRAL AMOUNTS & ELECTION TIMING:
The deferred compensation arrangement will be provided as a benefit enhancement for key executives and
members of the Board of Directors allowing deferrals of up to 100% of annual compensation. Deferral elections
must be made prior to January 1st of the year in which the deferred compensation is earned.
Deferrals will be invested into the Merrill Lynch- trusteed permissible investment options under the oversight of
Merrill Lynch and at the direction of the participant. Individuals may direct their deferral